Geoff Otto

13.9k total citations
45 papers, 2.6k citations indexed

About

Geoff Otto is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Geoff Otto has authored 45 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 22 papers in Cancer Research and 21 papers in Molecular Biology. Recurrent topics in Geoff Otto's work include Cancer Genomics and Diagnostics (20 papers), Lung Cancer Treatments and Mutations (7 papers) and Pancreatic and Hepatic Oncology Research (5 papers). Geoff Otto is often cited by papers focused on Cancer Genomics and Diagnostics (20 papers), Lung Cancer Treatments and Mutations (7 papers) and Pancreatic and Hepatic Oncology Research (5 papers). Geoff Otto collaborates with scholars based in United States, Germany and Canada. Geoff Otto's co-authors include Joseph D. Puglisi, Peter J. Lukavsky, Doron Lipson, Jeffrey S. Ross, Philip J. Stephens, Vincent A. Miller, Roman Yelensky, Insil Kim, Gary A. Palmer and Peter Sarnow and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Geoff Otto

44 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Geoff Otto United States	20	1.2k	953	581	517	468	45	2.6k
Thomas McKee Switzerland	32	864 0.7×	616 0.6×	279 0.5×	218 0.4×	254 0.5×	96	3.0k
Shigeto Kawauchi Japan	32	997 0.8×	745 0.8×	551 0.9×	551 1.1×	537 1.1×	106	2.4k
Jonathan S. Zager United States	46	1.9k 1.5×	4.4k 4.6×	940 1.6×	346 0.7×	534 1.1×	288	6.3k
Lee D. Cranmer United States	30	1.1k 0.9×	1.9k 2.0×	869 1.5×	333 0.6×	144 0.3×	127	3.3k
Steven E. Finkelstein United States	32	982 0.8×	4.0k 4.2×	998 1.7×	226 0.4×	423 0.9×	71	6.6k
Gabriele Palmedo Germany	27	634 0.5×	1.0k 1.1×	601 1.0×	185 0.4×	232 0.5×	58	2.5k
Il‐mi Okazaki Japan	27	1.1k 0.9×	1.7k 1.8×	249 0.4×	253 0.5×	303 0.6×	37	3.9k
Gal Markel Israel	41	1.5k 1.3×	2.5k 2.7×	354 0.6×	343 0.7×	380 0.8×	126	5.8k
Eric Angevin France	38	3.8k 3.2×	1.7k 1.8×	814 1.4×	1.7k 3.3×	248 0.5×	140	6.5k
Marie‐Anne Bründler Canada	24	510 0.4×	271 0.3×	472 0.8×	168 0.3×	264 0.6×	84	2.2k

Countries citing papers authored by Geoff Otto

Since Specialization

Citations

This map shows the geographic impact of Geoff Otto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Geoff Otto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Geoff Otto more than expected).

Fields of papers citing papers by Geoff Otto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Geoff Otto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Geoff Otto. The network helps show where Geoff Otto may publish in the future.

Co-authorship network of co-authors of Geoff Otto

This figure shows the co-authorship network connecting the top 25 collaborators of Geoff Otto. A scholar is included among the top collaborators of Geoff Otto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Geoff Otto. Geoff Otto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tarlock, Katherine, Shan Zhong, Yuting He, et al.. (2018). Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profiling. Oncotarget. 9(41). 26417–26430. 21 indexed citations

Fabrizio, David, Daniel S. Lieber, Christine M. Malboeuf, et al.. (2018). Abstract 5706: A blood-based next-generation sequencing assay to determine tumor mutational burden (bTMB) is associated with benefit to an anti-PD-L1 inhibitor, atezolizumab. Cancer Research. 78(13_Supplement). 5706–5706. 28 indexed citations

Fabrizio, David, Christine M. Malboeuf, Daniel S. Lieber, et al.. (2017). Analytic validation of a next generation sequencing assay to identify tumor mutational burden from blood (bTMB) to support investigation of an anti-PD-L1 agent, atezolizumab, in a first line non-small cell lung cancer trial (BFAST). Annals of Oncology. 28. v27–v27. 14 indexed citations

Tarlock, Katherine, Yuting He, James Sun, et al.. (2017). Recurrent Copy Number Variants Are Highly Prevalent in Acute Myeloid Leukemia. Blood. 130. 3800–3800. 1 indexed citations

Gandara, David R., Marcin Kowanetz, Tony Mok, et al.. (2017). Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK). Annals of Oncology. 28. v460–v460. 62 indexed citations

Ross, Jeffrey S., Sunil Badve, Kai Wang, et al.. (2015). Genomic Profiling of Advanced-Stage, Metaplastic Breast Carcinoma by Next-Generation Sequencing Reveals Frequent, Targetable Genomic Abnormalities and Potential New Treatment Options. Archives of Pathology & Laboratory Medicine. 139(5). 642–649. 55 indexed citations

Lovly, Christine M., Abha A. Gupta, Doron Lipson, et al.. (2014). Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions. Cancer Discovery. 4(8). 889–895. 303 indexed citations

Ross, Jeffrey S., Kai Wang, Christine E. Sheehan, et al.. (2014). Comprehensive Genomic Profiling of Relapsed and Metastatic Adenoid Cystic Carcinomas by Next-generation Sequencing Reveals Potential New Routes to Targeted Therapies. The American Journal of Surgical Pathology. 38(2). 235–238. 50 indexed citations

Ross, Jeffrey S., Kai Wang, Geoff Otto, et al.. (2014). Targeted next-generation sequencing (NGS) of carcinoma of unknown primary site (CUP): Actionable genomic alterations (GA) and new routes to targeted therapies.. Journal of Clinical Oncology. 32(15_suppl). 11048–11048. 1 indexed citations

10.

Wang, Kai, Michelle Nahas, Roman Yelensky, et al.. (2014). Novel Chromatin Modifying Gene Alterations and Significant Survival Association of ATM and P53 in Mantle Cell Lymphoma. Blood. 124(21). 3033–3033. 2 indexed citations

11.

Hutchinson, Katherine E., Doron Lipson, Philip J. Stephens, et al.. (2013). BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition. Clinical Cancer Research. 19(24). 6696–6702. 124 indexed citations

12.

Ross, Jeffrey S., Kai Wang, Rami N. Al‐Rohil, et al.. (2013). Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy. Modern Pathology. 27(2). 271–280. 119 indexed citations

13.

Ross, Jeffrey S., Kai Wang, Christine E. Sheehan, et al.. (2013). Relapsed Classic E-Cadherin ( CDH1 )–Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 ( ERBB2 ) Gene Mutations. Clinical Cancer Research. 19(10). 2668–2676. 96 indexed citations

14.

Miller, Vincent A., Jeffrey S. Ross, Kai Wang, et al.. (2013). Use of next-generation sequencing (NGS) to identify actionable genomic alterations (GA) in diverse solid tumor types: The Foundation Medicine (FMI) experience with 2,200+ clinical samples.. Journal of Clinical Oncology. 31(15_suppl). 11020–11020. 5 indexed citations

15.

Peled, Nir, Gary A. Palmer, Fred R. Hirsch, et al.. (2012). Next-Generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib-Sensitive ALK Rearrangement in a Patient with Metastatic Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 7(9). e14–e16. 102 indexed citations

16.

Otto, Geoff, et al.. (2007). Akutes Hämoperitoneum bei einer spontanen Tumorruptur als Erstmanifestation eines hepatozellulären Karzinoms. Zeitschrift für Gastroenterologie. 45(7). 615–619. 2 indexed citations

17.

Otto, Geoff & Joseph D. Puglisi. (2004). The Pathway of HCV IRES-Mediated Translation Initiation. Cell. 119(3). 369–380. 210 indexed citations

18.

Lukavsky, Peter J., Insil Kim, Geoff Otto, & Joseph D. Puglisi. (2003). Structure of HCV IRES domain II determined by NMR. Nature Structural & Molecular Biology. 10(12). 1033–1038. 237 indexed citations

19.

Otto, Geoff, Peter J. Lukavsky, Alissa M. Lancaster, Peter Sarnow, & Joseph D. Puglisi. (2002). Ribosomal proteins mediate the hepatitis C virus IRES???HeLa 40S interaction. RNA. 8(7). 913–923. 85 indexed citations

20.

Puglisi, Joseph D., et al.. (2001). Structural and functional investigation of the Hepatitis C virus IRES. Nucleic Acids Symposium Series. 1(1). 263–264. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact